Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study

I Dotan, Y Ron, H Yanai, S Becker… - Inflammatory bowel …, 2014 - academic.oup.com
Background Infliximab (IFX) is effective therapy for ulcerative colitis and Crohn's disease, but
it may be associated with side effects and loss of response. One loss of response …
被引用次数：289 相关文章

Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study

I Dotan, Y Ron, H Yanai, S Becker… - Inflammatory …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Infliximab (IFX) is effective therapy for ulcerative colitis and Crohn's disease, but
it may be associated with side effects and loss of response. One loss of response …

[引用][C] Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease

I Dotan, Y Ron, H Yanai, S Becker, S Fishman… - Inflammatory Bowel …, 2014 - cir.nii.ac.jp

Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study.

I Dotan, Y Ron, H Yanai, S Becker… - Inflammatory Bowel …, 2014 - europepmc.org
Background Infliximab (IFX) is effective therapy for ulcerative colitis and Crohn's disease, but
it may be associated with side effects and loss of response. One loss of response …